Study guide
5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections
Board Certified Pediatric Pharmacy Specialist BCPPS
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Pediatric Patient Characteristics — Growth, Anthropometrics & Perinatal Exposure
1.1 Normal Growth, Development & Growth-Chart Interpretation 1.2 Anthropometrics: Body Surface Area, Dosing Weights & Maximum-Dose Caps 1.3 Medication Use in Pregnancy and Lactation
2 Chapter 2: Developmental Pharmacokinetics & Neonatal Principles
2.1 Developmental PK: Absorption, Distribution & Body Water Dynamics 2.2 Hepatic Metabolism & CYP/UGT Isoenzyme Maturation 2.3 Renal Function Maturation & Glomerular Filtration Development
3 Chapter 3: Neonatal Critical Care & Prematurity Complications
3.1 Neonatal Sepsis & Meningitis (Early-Onset vs Late-Onset Sepsis) 3.2 Respiratory Distress Syndrome, Surfactant & Bronchopulmonary Dysplasia 3.3 Patent Ductus Arteriosus, Apnea of Prematurity & Necrotizing Enterocolitis
4 Chapter 4: Pediatric Infectious Diseases — Respiratory & ENT Infections
4.1 Acute Otitis Media, Sinusitis & Pharyngitis 4.2 Pediatric Community-Acquired Pneumonia & Parapneumonic Effusion 4.3 Bronchiolitis, RSV Prevention (Nirsevimab, Clesrovimab, Palivizumab) & Viral Lower Respiratory Infections
5 Chapter 5: Pediatric Infectious Diseases — Systemic, Bone & CNS Infections
5.1 Pediatric Meningitis, Encephalitis & Brain Abscess 5.2 Skin, Soft Tissue, Osteomyelitis & Septic Arthritis 5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections
6 Chapter 6: Pediatric Pulmonary Medicine — Asthma & Status Asthmaticus
6.1 Chronic Pediatric Asthma Assessment & Stepwise Outpatient Pharmacotherapy 6.2 Status Asthmaticus & Acute Exacerbation Pharmacotherapy in ED/PICU 6.3 Aerosol Drug Delivery, Spacers & Specialized Inhalation Devices
7 Chapter 7: Cystic Fibrosis & Chronic Pediatric Respiratory Disorders
7.1 Pathophysiology, Diagnosis & Airway Clearance in Cystic Fibrosis 7.2 CFTR Modulator Therapies & Monitoring 7.3 CF Pulmonary Exacerbations, Chronic Infection Management & Comorbidities
8 Chapter 8: Pediatric Cardiology & Hemodynamics
8.1 Congenital Heart Defects & Ductal-Dependent Lesions 8.2 Pediatric Heart Failure & Cardiomyopathies 8.3 Pediatric Arrhythmias & Syncope Management
9 Chapter 9: Pediatric Resuscitation, Shock & Critical Care Support
9.1 PALS Resuscitation Algorithms & Cardiac Arrest Pharmacotherapy 9.2 Pediatric Shock States & Vasoactive / Inotropic Selection 9.3 Extracorporeal Membrane Oxygenation (ECMO) & Critical Care PK
10 Chapter 10: Pediatric Neurology & Psychiatric Disorders
10.1 Neonatal Seizures & Pediatric Status Epilepticus 10.2 Pediatric Epilepsy Syndromes & Maintenance Anticonvulsants 10.3 Attention-Deficit/Hyperactivity Disorder (ADHD) & Pediatric Mood Disorders
11 Chapter 11: Pediatric Endocrinology & Metabolic Disorders
11.1 Pediatric Type 1 Diabetes Mellitus Management & Insulin Technologies 11.2 Diabetic Ketoacidosis (DKA) Protocols & Cerebral Edema Prevention 11.3 Growth Hormone, Pubertal Disorders & Congenital Adrenal Hyperplasia
12 Chapter 12: Pediatric Hematology, Oncology & Supportive Care
12.1 Sickle Cell Disease: Vaso-occlusive Crises & Disease-Modifying Therapies 12.2 Pediatric Acute Lymphoblastic Leukemia (ALL) & Chemotherapy Toxicities 12.3 Oncologic Emergencies: Tumor Lysis Syndrome & Supportive Care
13 Chapter 13: Pediatric Medication Safety & Error Prevention
13.1 High-Alert Pediatric Medications & Ten-Fold Dosing Calculation Traps 13.2 Smart Infusion Pumps & Dose Error Reduction Systems (DERS) 13.3 Medication Reconciliation & Pediatric Care Transitions
14 Chapter 14: Pediatric Compounding & Formulation Technology
14.1 Non-Sterile Compounding (USP <795>) & Liquid Formulations 14.2 Sterile Compounding (USP <797>) & Micro-Dosing Considerations 14.3 Hazardous Drug Handling (USP <800>) & Excipient Toxicities
15 Chapter 15: Fluids, Electrolytes & Clinical Nutrition Support
15.1 Fluid Requirements, Dehydration Assessment & Maintenance Therapy 15.2 Electrolyte Disturbances: Sodium, Potassium & Calcium Management 15.3 Pediatric & Neonatal Parenteral Nutrition (PN) Formulation
16 Chapter 16: Pediatric Pain Management, Sedation & Delirium
16.1 Age-Specific Pain Assessment Tools & Analgesic Selection 16.2 Procedural Sedation & Rapid Sequence Intubation in Children 16.3 PICU Delirium, Iatrogenic Withdrawal & Weaning Strategies
17 Chapter 17: Biostatistics & Study Design in Pediatric Research
17.1 Observational vs Experimental Pediatric Study Designs 17.2 Biostatistical Testing, Power & Sample Size in Small Pediatric Cohorts 17.3 Diagnostic Testing, Sensitivity, Specificity & Predictive Values
18 Chapter 18: Pediatric Evidence Appraisal, Regulatory Framework & Ethics
18.1 Pediatric Drug Legislation: BPCA, PREA & Labeling Nuances 18.2 Institutional Review Boards (IRB), Assent & Informed Consent in Minors 18.3 Evaluating Clinical Practice Guidelines & Formulating Off-Label Recommendations
19 Chapter 19: Pediatric Education, Health Literacy & Communication
19.1 Caregiver Health Literacy & Pediatric Medication Adherence 19.2 Interprofessional Education & Clinical Teaching Strategies 19.3 Developing Age-Appropriate Patient Educational Materials
20 Chapter 20: Pediatric Immunizations & Public Health Advocacy
20.1 ACIP Pediatric Immunization Schedule: Routine Childhood Vaccines 20.2 Adolescent Immunizations, Vaccine Hesitancy & Catch-Up Schedules 20.3 Pediatric Public Health Disparities & Special Population Advocacy
21 Chapter 21: Pediatric Practice Management — Laboratory Stewardship, Pharmacoeconomics & Informatics
21.1 Pediatric Laboratory Practices: Blood Conservation, Sampling Timing & Age-Specific Reference Intervals 21.2 Pharmacoeconomics, Formulary Management & Cost-Containment in Pediatrics 21.3 Clinical Informatics, CPOE Decision Support & Drug Shortage Management
5.3 Pediatric Sepsis, Febrile Neutropenia & Central Line-Associated Bloodstream Infections
Key Takeaways Explain This Topic AI
The Surviving Sepsis Campaign International Guidelines for pediatric sepsis mandate administration of empiric broad-spectrum IV antimicrobials within 1 hour of recognition for septic shock, and within 3 hours for sepsis-induced organ dysfunction without shock.
Pediatric febrile neutropenia (FN) is defined as a single temperature >=38.3 C (or >=38.0 C sustained >1 hour) with an ANC <500 cells/mm3 (or expected to fall <500); high-risk patients require immediate hospitalization and empiric IV antipseudomonal beta-lactam monotherapy (cefepime, piperacillin-tazobactam, or meropenem).
Empiric vancomycin should NOT be routinely added to initial pediatric FN regimens; vancomycin is strictly indicated only for hemodynamic instability, clinically suspected catheter-tunnel/pocket infection, Gram-positive blood cultures, known MRSA colonization, or severe mucositis.
In central line-associated bloodstream infections (CLABSI), immediate catheter removal is mandatory for Staphylococcus aureus, Candida species, Pseudomonas aeruginosa, non-tuberculous mycobacteria, tunnel/pocket infection, or septic shock; antimicrobial lock therapy is reserved for salvageable lines infected with low-virulence organisms (e.g., CoNS).
Fluid resuscitation in pediatric septic shock utilizes 10-20 mL/kg aliquots of balanced crystalloids (Lactated Ringer's or Plasma-Lyte) over 5-20 minutes, titrated to clinical perfusion targets while monitoring for hepatomegaly and crackles, with epinephrine (cold shock) or norepinephrine (warm shock) as first-line inotropes.
Last updated: September 2026
5.3 Pediatric Sepsis, Febrile Neutropenia & CLABSI
Quick Answer: The Surviving Sepsis Campaign mandates administering empiric broad-spectrum IV antimicrobials within 1 hour for pediatric septic shock, and within 3 hours for sepsis with organ dysfunction without shock. Resuscitate with balanced crystalloids (10–20 mL/kg aliquots) , initiating epinephrine for cold shock or norepinephrine for warm shock . Pediatric febrile neutropenia (temp ≥38.3°C, ANC <500) requires urgent IV antipseudomonal beta-lactam monotherapy : cefepime (150 mg/kg/day divided q8h) or piperacillin-tazobactam (300–400 mg/kg/day divided q6–8h) ; add vancomycin only for shock, catheter site infection, or Gram-positive cultures. For CLABSI, prompt line removal is mandatory for S. aureus , Candida , P. aeruginosa , tunnel infections, or shock; catheter lock therapy is restricted to salvage with low-virulence organisms (CoNS).
1. Pediatric Sepsis & Septic Shock: Surviving Sepsis Campaign Guidelines
The 2020 Surviving Sepsis Campaign International Guidelines for the Management of Septic Shock and Sepsis-Associated Organ Dysfunction in Children established rigorous, time-critical bundles designed to abort microvascular collapse and multiorgan dysfunction syndrome (MODS). +-----------------------------------------------------------------------------------------+
- | Surviving Sepsis Timing & Resuscitation Bundles |
- +-----------------------------------------------------------------------------------------+
- | Clinical Status | Antimicrobial Timing Window | Resuscitation Priorities |
- |-----------------------------|-------------------------------|-----------------------------------|
- | Septic Shock | Administer within 1 HOUR | - Vascular / IO access |
- | (Hypotension, altered cap | of recognition | - Blood cultures PRIOR to abx |
- | refill, abnormal pulses) | | - 10-20 mL/kg balanced crystalloid|
- | | | - Early vasoactive infusions |
- | Sepsis-Associated Organ | Administer within 3 HOURS | - Targeted diagnostic workup |
- | Dysfunction (Without shock) | of recognition | - Close hemodynamic monitoring |
- | | | - Maintain organ perfusion |
- +-----------------------------------------------------------------------------------------+
- Fluid Resuscitation: Crystalloid Selection & Safety Limits
Fluid Type : Guidelines recommend balanced crystalloids (e.g., Lactated Ringer's or Plasma-Lyte ) over 0.9% normal saline. High-volume 0.9% normal saline infuses large supranormal chloride loads ( 154 mEq/L 154 \text{ mEq/L} 154 mEq/L ), triggering hyperchloremic metabolic acidosis , renal cortical vasoconstriction, and increased rates of acute kidney injury.
Administration Rate : Infuse in 10 to 20 mL/kg aliquots over 5 to 20 minutes.
Fluid Overload Monitoring : Reassess the child after each aliquot for signs of fluid responsiveness (improved capillary refill, normalization of heart rate, widening pulse pressure, urine output > 1 mL/kg/h >1 \text{ mL/kg/h} > 1 mL/kg/h ) and signs of fluid overload ( hepatomegaly, new gallop rhythm, fine pulmonary crackles, worsening work of breathing ). Discontinue fluid boluses immediately if fluid overload emerges.
Vasoactive Support: Cold Shock vs Warm Shock
Unlike adult septic shock (which is predominantly hyperdynamic "warm shock" with low systemic vascular resistance), pediatric septic shock presents as "cold shock" in ~60% of cases , characterized by profound myocardial depression, low cardiac output, and severe compensatory vasoconstriction. +-----------------------------------------------------------------------------------------+
- | Vasoactive Selection in Pediatric Septic Shock |
- +-----------------------------------------------------------------------------------------+
- | Shock Phenotype | Clinical Presentation | First-Line Vasoactive Agent |
- |---------------------|-------------------------------------|-------------------------------------|
- | Cold Shock | Cold, clammy extremities; capillary | Epinephrine infusion |
- | (Low cardiac index, | refill >2 seconds; diminished | (0.05 to 0.3 mcg/kg/min) |
- | high SVR) | peripheral pulses; narrow pulse | Potent beta-1 inotropy with modest |
- | | pressure | alpha-1 vasoconstriction |
- | Warm Shock | Warm, flushed extremities; flash | Norepinephrine infusion |
- | (High cardiac index,| capillary refill (<1 second); | (0.05 to 0.5 mcg/kg/min) |
- | low SVR / vasoplegia| bounding peripheral pulses; wide | Potent alpha-1 vasoconstriction with|
- | | pulse pressure | modest beta-1 support |
- +-----------------------------------------------------------------------------------------+
Note: Dopamine is no longer recommended as first-line therapy because clinical trials show increased mortality and higher rates of healthcare-associated infections compared to epinephrine.
2. Pediatric Febrile Neutropenia (FN)
In pediatric oncology and hematopoietic stem cell transplantation (HSCT) patients, chemotherapy-induced neutropenia strips the host of primary innate phagocytic defenses. Because neutrophils are responsible for erythema, swelling, and purulent exudates, fever is often the sole presenting sign of life-threatening bacteremia .
Definitions & The Absolute Neutrophil Count (ANC)
Fever : A single oral temperature ≥38.3°C (101.0°F) OR a temperature ≥38.0°C (100.4°F) sustained over at least 1 hour .
Patient Safety Warning: Rectal temperatures and rectal medications are strictly contraindicated in neutropenic patients due to mucosal fragility; micro-tears in rectal mucosa allow enteric bacteria ( Enterobacteriaceae , Pseudomonas ) to translocate directly into the bloodstream.
Neutropenia : An ANC <500 cells/mm³ (or < 0.5 × 10 9 / L <0.5 \times 10^9/\text{L} < 0.5 × 1 0 9 / L ) OR an ANC <1000 cells/mm³ with a projected decline to <500 cells/mm³ within 24 to 48 hours. ANC = WBC (cells/mcL) × ( % Segmented Neutrophils + % Bands 100 ) \text{ANC} = \text{WBC (cells/mcL)} \times \left( \frac{\% \text{Segmented Neutrophils} + \% \text{Bands}}{100} \right) ANC = WBC (cells/mcL) × ( 100 % Segmented Neutrophils + % Bands )
High-Risk vs Low-Risk Stratification
Pediatric guidelines (ASCO/IDSA and International Pediatric FN Guidelines) stratify patients into risk categories:
High-Risk FN : Anticipated prolonged neutropenia (>7 days), profound neutropenia (ANC <100 cells/mm³), acute myeloid leukemia (AML), relapsed leukemia, HSCT conditioning, hemodynamic instability, medical comorbidities, high-grade mucositis, or new pulmonary infiltrates. Mandates immediate hospitalization and parenteral antipseudomonal beta-lactam monotherapy.
Low-Risk FN : Anticipated brief neutropenia (<7 days), solid tumors receiving maintenance cycles, ANC expected to recover rapidly, hemodynamically stable, no focal source. Select patients may qualify for outpatient management in validated protocols. +-----------------------------------------------------------------------------------------+
- | Empiric Beta-Lactam Monotherapy Regimens in High-Risk FN |
- +-----------------------------------------------------------------------------------------+
- | Drug | Pediatric FN Dosing | Spectrum & Clinical Features |
- |---------------------|-------------------------------------|-------------------------------------|
- | Cefepime (IV) | 150 mg/kg/day divided every 8 hours | Potent Pseudomonas & Gram-negative |
- | | (50 mg/kg/dose q8h; max 2000 mg) | bacilli; excellent MSSA and strep |
- | | | coverage. Standard first-line. |
- | Piperacillin- | 300 to 400 mg/kg/day piperacillin | Antipseudomonal plus broad enteric |
- | tazobactam (IV) | divided q6-8h (Max 16 g/day) | anaerobic coverage. Preferred if |
- | | | typhlitis / GI symptoms present. |
- | Meropenem (IV) | 60 to 120 mg/kg/day divided q8h | Broadest spectrum; reserved for |
- | | (20-40 mg/kg/dose q8h; max 2000 mg) | septic shock, ESBL colonization, |
- | | | or severe beta-lactam allergy. |
- +-----------------------------------------------------------------------------------------+
- The Rationale for Monotherapy vs Dual Therapy
Historic protocols combined an antipseudomonal beta-lactam with an aminoglycoside (e.g., tobramycin). Multiple large randomized pediatric trials and Cochrane meta-analyses demonstrated that beta-lactam monotherapy achieves identical survival and infection clearance compared to beta-lactam plus aminoglycoside combinations , while completely avoiding aminoglycoside-associated nephrotoxicity and ototoxicity. Aminoglycosides are reserved for patients with septic shock or known resistant pathogens.
Indications for Empiric Vancomycin Addition & Stewardship Rules
Routine empiric addition of vancomycin to initial pediatric FN regimens provides no survival advantage and increases rates of acute kidney injury and vancomycin-resistant enterococci (VRE). +-----------------------------------------------------------------------------------------+
- | Specific Criteria for Adding Empiric Vancomycin in FN |
- +-----------------------------------------------------------------------------------------+
- | Indication 1 | Hemodynamic instability, sepsis-induced hypotension, or septic shock. |
- | Indication 2 | Clinically apparent central venous catheter site infection (purulence, |
- | | erythema, tenderness at the tunnel or port pocket). |
- | Indication 3 | Preliminary blood cultures positive for Gram-positive cocci (prior to ID)|
- | Indication 4 | Known colonization with MRSA or penicillin-resistant S. pneumoniae. |
- | Indication 5 | Severe oral mucositis (Grade 3/4) predisposing to viridans streptococcal |
- | | bacteremia and catastrophic toxic shock. |
- | Indication 6 | Apparent skin, soft tissue, or bone/joint infection. |
- +-----------------------------------------------------------------------------------------+
The 48-Hour Stewardship Discontinuation Rule: If vancomycin was initiated at presentation and subsequent blood cultures show no Gram-positive bacterial growth at 48 hours , vancomycin MUST be discontinued immediately , even if the patient remains febrile.
3. Central Line-Associated Bloodstream Infections (CLABSI)
Central venous access devices (tunneled catheters [Broviac, Hickman], implanted ports [Port-a-Cath], and PICCs) are essential for chemotherapy and supportive care but represent the primary conduit for intraluminal and extraluminal bacterial biofilm colonization. +-----------------------------------------------------------------------------------------+
- | CLABSI Microbiology & Catheter Management Strategy |
- +-----------------------------------------------------------------------------------------+
- | Pathogen | Relative Frequency | Management: Removal vs Salvage |
- |------------------------------|--------------------|-------------------------------------|
- | Coagulase-Negative Staph | Most common | Line salvage possible in stable pts.|
- | (S. epidermidis; CoNS) | (~30-40%) | Systemic abx + lock therapy x 10-14d|
- | Staphylococcus aureus | High virulence | MANDATORY LINE REMOVAL. |
- | (MSSA and MRSA) | (~15-20%) | High risk of endocarditis/emboli. |
- | Candida species | High mortality | MANDATORY LINE REMOVAL. |
- | (C. albicans, parapsilosis) | (~10-15%) | Fungal biofilms cannot be sterilized|
- | Pseudomonas aeruginosa | Enteric / nosocomial| MANDATORY LINE REMOVAL. |
- | | (~5-10%) | High relapse and tissue invasion. |
- | Enterobacteriaceae | Enteric | Salvage possible if uncomplicated; |
- | (E. coli, Klebsiella) | (~15-20%) | remove if bacteremia persists >72h. |
- | Non-tuberculous Mycobacteria | Opportunistic | MANDATORY LINE REMOVAL. |
- +-----------------------------------------------------------------------------------------+
- Mandatory Indications for Central Venous Catheter Removal
Per IDSA catheter-related infection guidelines, central lines MUST be promptly removed in the presence of:
Blood cultures yielding Staphylococcus aureus , Candida species , Pseudomonas aeruginosa , or non-tuberculous mycobacteria .
Severe sepsis, septic shock , or hemodynamic instability attributable to the line.
Suppurative thrombophlebitis , endocarditis, or metastatic septic emboli.
Tunnel infection or subcutaneous port pocket abscess (infection tracking beyond the catheter exit site cannot be cleared with systemic antibiotics).
Persistent bacteremia >72 hours despite appropriate targeted antimicrobial therapy.
Catheter Salvage & Antimicrobial Lock Therapy (ALT)
When vascular access is critical and the infecting pathogen is low-virulence (e.g., coagulase-negative staphylococci) in an uncomplicated, stable patient without tunnel tract involvement, catheter salvage may be attempted using systemic therapy combined with Antimicrobial Lock Therapy (ALT) . +-----------------------------------------------------------------------------------------+
- | Antimicrobial Lock Therapy (ALT) Formulations |
- +-----------------------------------------------------------------------------------------+
- | Lock Agent | Typical Concentration | Clinical Nuances |
- |----------------------|-------------------------------------|------------------------------------|
- | Vancomycin Lock | 2 to 5 mg/mL in normal saline | Combined with heparin (10-100 U/mL)|
- | | | Superb against CoNS biofilms. |
- | Cefazolin Lock | 5 to 10 mg/mL in normal saline | Combined with heparin for MSSA. |
- | Gentamicin Lock | 1 to 2 mg/mL in normal saline | Utilized for sensitive GNBs. |
- | 70% Ethanol Lock | 70% Ethyl alcohol | Denatures biofilm proteins/lipids; |
- | | (Preservative-free) | risk of catheter degradation & |
- | | | plasma protein precipitation. |
- +-----------------------------------------------------------------------------------------+
Mechanism of Action : Bacteria in biofilms enter a slow-growing, metabolically quiescent state protected by an extracellular polysaccharide slime layer, resisting standard serum antibiotic levels. ALT instills concentrations 100 to 1000 times higher than the MIC directly into the catheter lumen, dwelling for 8 to 24 hours per day for 10 to 14 days .
Ethanol Lock Pearls : 70% ethanol is a non-antibiotic agent that rapidly dissolves lipid envelopes and denatures proteins across bacteria and fungi, preventing antimicrobial resistance selection. However, clinicians must be alert to risks: prolonged exposure can compromise the tensile strength of certain polyurethane catheters, cause intraluminal catheter occlusions due to plasma protein precipitation, and produce systemic intoxication if accidentally flushed into low-birth-weight neonates.